regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-04. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
According to Mathieu Boisvert, nidana 3-10 correlate with the five skandhas. Boisvert notes that while sañña, "perception", is not found in the twelvefold chain, it does play a role in the processes described by the chain, particularly between feeling and the arising of samskaras. Likewise, Waldron notes that the anusaya, "underlying tendencies, are the link between the cognitive processes of phassa ("contact") and vedana (feeling), and the afflictive responses of tanha ("craving") and upadana ("grasping").
== Discovery == It is known that rapid heat hardening can be elicited by a brief exposure of cells to sub-lethal high temperature, which in turn provides protection from subsequent and more severe temperature. In 1962, Italian geneticist Ferruccio Ritossa reported that heat and the metabolic uncoupler 2,4-dinitrophenol induced a characteristic pattern of "puffing" in the chromosomes of Drosophila. This discovery eventually led to the identification of the heat-shock proteins (HSP) or stress proteins whose expression this puffing represented. Increased synthesis of selected proteins in Drosophila cells following stresses such as heat shock was first reported in 1974. In 1974, Tissieres, Mitchell and Tracy discovered that heat-shock induces the production of a small number of proteins and inhibits the production of most others. This initial biochemical finding gave rise to a large number of studies on the induction of heat shock and its biological role. Heat shock proteins often function as chaperones in the refolding of proteins damaged by heat stress. Heat shock proteins have been found in all species examined, from bacteria to humans, suggesting that they evolved very early and have an important function.
== Selected publications == Eaton, D. L., & Groopman, J. D. (Eds.). (1994). The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance. Academic Press. ISBN 978-0122282553. Ramsdell, H. S., & Eaton, D. L. (1990). Species differences in aflatoxin B1 metabolism in hepatic microsomes and hepatocytes from monkey, rat, mouse, and chicken. Toxicol. Appl. Pharmacol., 105(2), 216–225. Gallagher, E. P., Wienkers, L. C., Stapleton, P. L., Kunze, K. L., & Eaton, D. L. (1994). Role of human microsomal cytochrome P4503A4 and 1A2 in the bioactivation of aflatoxin B1. Cancer Research, 54(1), 101–108. Eaton, D. L., & Bammler, T. K. (1999). Concise review of the glutathione S-transferases and their significance in toxicology. Toxicological Sciences, 49(2), 156–164. National Academies of Sciences, Engineering, and Medicine; Eaton, D. L. et al. (Eds.). (2018). Public Health Consequences of E-Cigarettes. The National Academies Press. ISBN 978-0309468336. Chang, S.-Y., Weber, E. J., Sidorenko, V. S., Chapron, A., Yeung, C. K., Gao, C., Mao, Q., Shen, D., Wang, J., Rosenquist, T. A., Dickman, K. G., Grollman, A. P., *Kelly, E. J., Himmelfarb, J., & Eaton, D. L. (2017). Human liver-kidney microphysiological system for quantum dot toxicity testing and aristolochic acid nephrotoxicity modeling. JCI Insight, 2(6), e91320 Omenn GS & Eaton DL. (2022). The Risk Assessment-Risk Management Paradigm. IN: M. Robson and WA Toscano, Ed. Risk Assessment for Environmental Health, 2nd Edition, Chapter 2, John Wiley & Sons, New York.
A mimotope is often a peptide, and mimics the structure of an epitope. Because of this property it causes an antibody response similar to the one elicited by the epitope. An antibody for a given epitope antigen will recognize a mimotope which mimics that epitope. Mimotopes are commonly obtained from phage display libraries through biopanning. Vaccines utilizing mimotopes are being developed. Mimotopes are a kind of peptide aptamers. When the term mimotope was coined by Mario Geysen in 1986, it was used to describe peptides mimicking epitopes. However, this concept has been extended to refer peptide mimic of all types of binding sites. As the mimic of binding site, mimotope analysis has been widely used in mapping epitopes, identifying drug target and inferring protein interaction networks. Furthermore, mimotope has also shown its potential in the development of new diagnostics, therapeutics and vaccines. In addition, special affinities mediated by mimotopes to various semiconductors and other materials have shown very encouraging promise in new material and new energy studies. Gathering information on mimotopes into a special database therefore deserves. In 2010, the MimoDB database version 1.0 was released. It had 10716 peptides grouped into 1229 sets. These peptides were extracted from biopanning results of phage-displayed random peptide libraries reported in 571 papers. The MimoDB database has been updated to the current version 2.0 very recently. In version 2.0, it has 15633 peptides collected from 849 papers and grouped into 1818 sets.
Sources: en.wikipedia.org
Using purified proteins on substrates including artificial lipid bilayers and flow-based adhesion assays, his lab discovered the first heterophilic (like-unlike) receptor–counter-receptor adhesion pairs in all of cell biology, including CD2–LFA-3 and LFA-1–ICAM. The LFA-1–ICAM interaction required Mg2+, and explained the Mg2+-dependence of cell adhesion in antigen recognition. Subsequently, Springer structurally resolved the LFA-1–ICAM-1 interaction, with Mg2+ at the ligand-binding interface.
Generally speaking single-particle measurement instruments desorb particles one at a time using a pulsed laser. The process is called laser desorption/ionization (LDI) and is the primary ionization method used for single-particle measurements. The main advantage of using LDI over thermal desorption, is the ability to analyze both non-refractory and refractory (e.g., mineral dust, soot) components of atmospheric aerosols. Laser vaporization allows precise laser firing when individual particles fly through the vaporization zone, and the systems are thus dubbed single particle mass spectrometers (SPMS). Several versions of SPMS have been reported, including the aerosol time-of-flight mass spectrometer (AToFMS), the laser mass analyzer for particles in the airborne state (LAMPAS), particle analysis by laser mass spectrometer (PALMS), the rapid single-particle mass spectrometer (RSMS), the bioaerosol mass spectrometer (BAMS) b194 Steele et al., 2003), the nanoaerosol mass spectrometer (NAMS), the single-particle laser ablation time-of-flight mass spectrometer (SPLAT), the single-particle aerosol mass spectrometer (SPAMS), and laser ablation aerosol particle time-of-flight mass spectrometer (LAAP-ToF-MS). Among the most commons of these instruments is the aerosol time-of-flight mass spectrometer (AToFMS).
== Caesium-134 == Caesium-134 has a half-life of 2.0650 years. It is produced both directly (at a very small yield because 134Xe is stable) as a fission product and via neutron capture from nonradioactive 133Cs (neutron capture cross section 29 barns), which is a common fission product. It is not produced by nuclear weapons because 133Cs is created by beta decay of original fission products long after the nuclear explosion is over. The combined yield of 133Cs and 134Cs is given as 6.7896%. The proportion between the two will change with continued neutron irradiation. 134Cs also captures neutrons with a cross section of 140 barns, becoming long-lived radioactive 135Cs. Caesium-134 undergoes beta decay (β−), producing stable 134Ba after emitting on average 2.23 gamma ray photons (mean energy 0.698 MeV).
=== Mechanism of action === Insulin glargine differs from human insulin by replacing asparagine with glycine in position 21 of the A-chain and by carboxy-terminal extension of B-chain by 2 arginine residues. The arginine amino acids shift the isoelectric point from a pH of 5.4 to 6.7, making the molecule more soluble at an acidic pH and less soluble at physiological pH. The isoelectric shift also allows for the subcutaneous injection of a clear solution. The glycine substitution prevents deamidation of the acid-sensitive asparagine at acidic pH. In the neutral subcutaneous space, higher-order aggregates form, resulting in a slow, peakless dissolution and absorption of insulin from the site of injection.
By establishing the presence of two distinct steps in the process the possibility of identifying the factors involved was established and led on to the identification of the importin family of NLS receptors and the GTPase Ran.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.